Most vaccines do both, but the balance varies dramatically depending on the vaccine. Some, like the measles vaccine, are 97% effective at preventing infection entirely. Others, like the COVID-19 vaccines, are far better at preventing severe symptoms than at blocking the virus from entering your body in the first place. Understanding why comes down to how your immune system fights pathogens at different stages.
Two Types of Immune Protection
When immunologists talk about vaccines, they distinguish between two levels of protection. The first, called sterilizing immunity, means the pathogen is eliminated before it can even replicate inside your cells. Antibodies intercept the virus or bacterium right at the point of entry, and the infection never takes hold. You don’t get sick, you don’t carry the pathogen, and you can’t pass it to anyone else.
The second level is protective immunity. Here, the pathogen does get in and starts replicating, but your immune system recognizes it quickly enough to shut things down before you develop serious symptoms. You might feel mildly ill or have no symptoms at all, but technically you were infected. In some cases, you can still transmit the pathogen to others during this window.
Both types rely on immune memory from vaccination. Your body “remembers” the pathogen and responds faster the second time around. The difference is whether that response is fast enough to stop infection at the gate or just fast enough to prevent it from becoming dangerous.
Why Some Vaccines Block Infection Better Than Others
The key factor is where antibodies are stationed. Pathogens that enter through your nose or throat encounter a defense system in the mucous membranes lining your respiratory tract. A specific type of antibody called IgA patrols these surfaces. Research shows that mucosal IgA has a broader ability to neutralize viruses than the antibodies circulating in your bloodstream, and it can block pathogens right at the entry point, reducing both infection and onward transmission.
Most injectable vaccines, however, primarily generate a different type of antibody (IgG) in your bloodstream. These systemic antibodies are excellent at catching a pathogen once it has entered deeper tissues, preventing it from reaching your lungs, brain, or other organs where it causes serious damage. But they’re not as effective at stopping the initial foothold in your nose or throat. This is why injected COVID-19 vaccines dramatically cut hospitalizations and deaths while offering more modest, shorter-lived protection against infection itself.
Vaccines that produce strong, lasting antibody responses right at the site of entry tend to provide something closer to sterilizing immunity. The measles vaccine is the classic example: two doses generate such robust, long-lasting immune responses that 97% of vaccinated people never become infected at all, even when directly exposed. People who do get measles despite vaccination tend to have milder illness.
Vaccines That Mostly Prevent Infection
A handful of vaccines come close to true sterilizing immunity. The measles vaccine is the gold standard, with two doses providing roughly 97% protection against infection. This is effective enough that mass vaccination can eliminate measles from entire populations. When enough people are immune at the infection-blocking level, the virus simply runs out of hosts, and transmission drops to zero.
The HPV vaccine tells a similar story. Clinical data show it is at least 97% effective at preventing persistent infections with the HPV strains responsible for most cervical cancers. Even a single dose provides protection statistically comparable to two doses. Because the vaccine stops persistent infection, not just symptoms, it prevents the long chain of events that leads from chronic viral infection to cancer years or decades later.
Vaccines That Mostly Prevent Severe Disease
COVID-19 vaccines are the most prominent recent example of vaccines that primarily reduce severity rather than block infection. The mRNA vaccines work through multiple mechanisms: they reduce the chance of initial infection, slow viral replication in people who do get infected, lower the amount of virus those people shed, and reduce symptoms like coughing and sneezing that spread the virus further. Each of these layers chips away at transmission, but none of them fully prevents it.
The protection against infection also fades faster than the protection against severe disease. Breakthrough infections (infections after vaccination) are common, though vaccinated people tend to carry less virus in their nasal passages and clear it more quickly. This partial, temporary reduction in transmission is a fundamentally different kind of protection than what the measles vaccine provides, and it has real consequences for public health strategy.
Whooping cough (pertussis) offers another instructive case. The current acellular vaccine prevents the hallmark symptoms of the disease, including the violent coughing fits and breathing difficulties. But animal studies raised concerns that vaccinated individuals might still carry the bacteria without symptoms, silently passing it along. Human data paints a more reassuring picture: studies of vaccinated children found that fewer than 1% carried the pertussis bacterium asymptomatically, a much lower rate than the 5 to 30% carriage seen in populations that received the older whole-cell vaccine. So the current vaccine does reduce carriage, just not as completely as it prevents symptoms.
Why This Distinction Matters for Herd Immunity
The practical difference between preventing infection and preventing symptoms reshapes how effectively mass vaccination can protect a community. For diseases like measles, where the vaccine blocks transmission, vaccinating enough people (typically 92 to 95% of the population) pushes the average number of new infections caused by each case below one. The disease fizzles out. This is the classic herd immunity threshold, and it works because immune people are essentially dead ends for the virus.
For pathogens like SARS-CoV-2, where vaccination reduces but does not eliminate transmission, this math breaks down. Vaccinated people can still get infected and pass the virus along, so even very high vaccination rates cannot drive transmission to zero. Mass vaccination delays and softens waves of infection rather than eliminating them. The population reaches an endemic equilibrium where the virus continues circulating, but most people have enough immunity (from vaccination, prior infection, or both) to avoid the worst outcomes.
This is not a failure of the vaccines. It reflects the biology of where the virus replicates, how long immunity lasts at mucosal surfaces, and how quickly the virus evolves. Systemic COVID-19 vaccination has saved millions of lives by preventing severe disease and death. But expecting it to eradicate the virus the way measles vaccination can eliminate measles was always unrealistic given how these vaccines generate immunity.
Nasal Vaccines and the Goal of Blocking Infection
Because the gap between infection prevention and symptom prevention comes down largely to where antibodies are produced, researchers are developing vaccines delivered directly to the nasal mucosa. The logic is straightforward: if you can build immune defenses right where respiratory viruses first land, you have a better shot at stopping infection before it starts. Intranasal vaccines stimulate both the mucosal immune system and the systemic immune system, potentially offering the best of both worlds.
This approach matters most for respiratory pathogens like influenza and SARS-CoV-2, where injected vaccines have always been better at preventing severe illness than preventing infection. A vaccine that could generate strong, durable IgA responses in the nose and throat could reduce not only disease but also transmission, bringing these pathogens closer to the kind of control we achieve with measles.
There is an interesting tradeoff, though. When systemic vaccination reduces how much virus replicates in your airways during a breakthrough infection, the milder infection generates a weaker mucosal immune response afterward. In other words, by doing its job of limiting viral replication, the injected vaccine may inadvertently reduce the strength of the natural mucosal immunity you would have built from that infection. This does not make vaccination harmful; it simply means that injectable vaccines and mucosal immunity operate through different, sometimes competing, pathways.